6 assets in Omenn Syndrome

Therapeutic assets addressing Omenn Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Busulfanum Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Fludarabine Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Melphalan Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Omenn Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)